<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>sinovac6k123104.txt
<DESCRIPTION>SINOVAC BIOTECH LTD. 6K, 12.31.04
<TEXT>






                                  UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                              Washington, DC 20549

                                    FORM 6-K
                                    --------

       REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
                    UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of December, 2004.

Commission File Number: 0-29031

                              SINOVAC BIOTECH LTD.
                              --------------------
                       (Name of Registrant in its charter)

                               ANTIGUA and BARBUDA
                               -------------------
         (State or other jurisdiction of incorporation or organization)

                               39 Shangdi Xi Road
                            Haidian District, Beijing
                                  China 100085
                            -------------------------
              (Address of principal executive offices and zip code)

                               Tel: 86-10-82890088
                               Fax: 86-10-62966910
                               -------------------
                      (Issuer's telephone and fax numbers)

Indicate by check mark whether the registrant  files or will file annual reports
under cover Form 20-F or Form 40-F

                           Form 20-F  X      Form 40-F
                                    -----             -----

Indicate by check mark whether the  registrant  by  furnishing  the  information
contained  in this  Form is  also  thereby  furnishing  the  information  to the
Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

                           Yes               No  X
                              -----            -----

If "Yes" is marked, indicate below the file number assigned to the registrant in
connection with Rule 12g3-2(b):  82-
                                    ------



<PAGE>






INDEX
-----

Item
----

1.   Financial Advisory Agreement with Credit Suisse Advisory Partners AG

2.   Press Release dated December 21, 2004 - Exhibit 99.1


Item 1.  Financial Advisory Agreement with Credit Suisse Advisory Partners AG
-----------------------------------------------------------------------------

Effective December 14, 2004, the Board of Directors of Sinovac Biotech Ltd. (the
"Company")  approved the Financial  Advisory  Agreement entered into between the
Company and Credit Suisse Advisory Partners AG ("Credit Suisse"), a 100% - owned
subsidiary of Credit Suisse Group headquartered in Zurich, Switzerland,  whereby
Credit  Suisse will act as the Company's  exclusive  financial  advisor.  Credit
Suisse Group is a leading global financial services company.

Item 2.  Press Release dated December 21, 2004 - 99.1
-----------------------------------------------------


                                   SIGNATURES
                                   ----------

Pursuant  to the  requirements  of the  Securities  Exchange  Act of  1934,  the
registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
undersigned, thereunto duly authorized.


                                                SINOVAC BIOTECH LTD.
                                                --------------------

Date:  December 28, 2004                        By:      /s/ Weidong Yin
                                                    ----------------------------
                                                    Weidong Yin, President, CEO
                                                    and a Director




</TEXT>
</DOCUMENT>
